NGT BioPharma Consultants understands the challenges companies face when selecting a clinical candidate to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of an asset’s attributes, including risks, to ensure critical experiments are prioritized. We can then provide a comprehensive plan to navigate the many interdependent preclinical activities, expediting your asset’s path into the clinic.

We leverage our collective expertise and extensive experience in small and large molecules (Mabs, duobodies, proteins, cell therapy, gene therapy as well as new modalities), to generate fit-for-purpose progression plans and provide this consultancy in close alignment with the expertise of NGT consultants experienced in Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.